1201898-17-0

Basic information

• Product Name: Vinflunine Tartrate
• Synonyms: Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2β,3β,4β,5α,12R,19β)-, (2R,3R)-2,3-dihydroxybutanedioate (1:x)
• CAS NO: 1201898-17-0
• Molecular Formula: C45H54F2N4O8.xC4H6O6
• Molecular Weight: 967.02
• Product Categories: Inhibitors
• Mol File: 1201898-17-0.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Vinflunine Tartrate(CAS DataBase Reference)
• NIST Chemistry Reference: Vinflunine Tartrate(1201898-17-0)
• EPA Substance Registry System: Vinflunine Tartrate(1201898-17-0)

Safety Data

• Hazardous Substances Data: 1201898-17-0(Hazardous Substances Data)

Usage

Description

Vinflunine Tartrate is a synthetic derivative of vinca alkaloids, a chemotherapy drug specifically designed to treat advanced or metastatic transitional cell carcinoma of the urothelial tract, including bladder cancer. It functions by disrupting the growth and spread of cancer cells within the body, offering a targeted approach to cancer treatment.

Uses

Used in Oncology:
Vinflunine Tartrate is used as an anticancer agent for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, particularly bladder cancer. It is administered through intravenous infusion and works by inhibiting the microtubule dynamics necessary for cell division, thereby preventing the proliferation and metastasis of cancer cells.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Vinflunine Tartrate is utilized as a key component in cancer therapeutics. Its development and production involve a meticulous process to ensure its efficacy and safety for patients. The drug's formulation and administration protocols are carefully designed to maximize its therapeutic benefits while managing potential side effects.
Common side effects associated with Vinflunine Tartrate include nausea, vomiting, constipation, and fatigue. It is crucial for patients to engage in a detailed discussion with their healthcare provider to understand the potential benefits and risks associated with the use of Vinflunine Tartrate in their treatment plan. This collaborative approach helps in making informed decisions and tailoring the treatment to the individual patient's needs and circumstances.

Relevant articles and documents

CRYSTALLINE FORM OF VINFLUNINE DITARTRATE

The present invention relates to a novel crystalline form of vinflunine, to a process for preparing it, and to its uses in the therapeutic field, in particular for treating cancer.